Description
Product Usage Information
Western Blotting: 1:1000
Immunoprecipitation: 1:100
Immunofluorescence (Immunocytochemistry): 1:800 - 1:3200
Flow Cytometry (Fixed/Permeabilized): 1:800 - 1:1600
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunoprecipitation, Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized)
Specificity / Sensitivity
GFI1 (E5J6J) Rabbit Monoclonal Antibody recognizes endogenous levels of total GFI1 protein. This antibody may detect a band of unknown identity at 40kDa.
Species Reactivity: Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human GFI1 protein.
Background
GFI1 and its homolog GFI1b are transcriptional repressors and important regulators of hematopoiesis (1). GFI1/GFI1b negatively regulate transcription by recruiting chromatin regulatory proteins including CoREST, the histone demethylase LSD1, and HDACs 1 and 2, which associate with the GFI1 proteins via their N-terminal SNAG repression domains (2,3). GFI1 is expressed in hematopoietic stem cells (HSCs), where it is necessary to restrict HSC proliferation and maintain functional integrity (4,5). It is also expressed in common lymphoid and myeloid progenitors, where it plays an essential role in lymphoid and granulo-monocytic differentiation (5,6). Indeed, knockout mice show impaired granulocytic differentiation and develop severe neutropenia, causing them to die quickly due to bacterial infection (7,8). In contrast, GFI1b is necessary for erythroid and megakaryocytic development and differentiation, and inactivation of GFI1b in mice leads to embryonic lethality (9). Unsurprisingly, the GFI1 proteins are implicated in multiple blood disorders, and GFI1 specifically is considered to be a predictor and therapeutic target for acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) (10). A GFI1 variant protein caused by a point mutation (S36N) may also confer a disposition to AML and accelerate disease progression (11,12). Interestingly, GFI1 has also been described to be an oncogenic driver for certain subsets of Group 3 medulloblastomas (13,14).
Alternate Names
FLJ94509; GFI-1; GFI1; GFI1A; growth factor independence-1; growth factor independent 1; growth factor independent 1 transcription repressor; growth factor independent 1 transcriptional repressor; Growth factor independent protein 1; SCN2; Zinc finger protein 163; Zinc finger protein Gfi-1; ZNF163
